Photosensitivity testing in children - 24/04/13
, Vigfus Sigurdsson, MD, PhD a, Carla A.F.M. Bruijnzeel-Koomen, MD, PhD a, Huib van Weelden, MSc a, Suzanne G.M.A. Pasmans, MD, PhD b
Reprint requests: Onno ten Berge, MD, Department of Dermatology, University Medical Center Utrecht, Heidelberglaan 100, Room G02.124, 3584 CX Utrecht, The Netherlands.Abstract |
Background |
Phototesting is an important diagnostic tool to objectify light-related symptoms. Data on phototesting procedures in children are scarce.
Objective |
The aim of this study was to evaluate phototest results in photosensitivity disorders in children.
Methods |
The phototest procedures are described. All children phototested in our department between 1995 and 2007 were included in this retrospective study. Children given the diagnosis of polymorphic light eruption (PLE) were selected for follow-up.
Results |
A total of 92 children (39 boys and 53 girls, age range 4-16 years) were successfully phototested. A photosensitivity disorder was confirmed in 56 children (61%, 24 boys and 32 girls). PLE was diagnosed in 39%, photosensitivity associated with atopic dermatitis in 23%, and erythropoietic protoporphyria in 23%. Other diagnoses were less common. Ten children with PLE were followed up for at least 5 years. Seven reported their photosensitivity had not changed over time, in two cases it had diminished, and in one patient the photosensitivity had disappeared.
Limitations |
Retrospective study design is a limitation.
Conclusion |
Phototesting in children is feasible when performed in a case- and child-dependent manner. PLE was the most prevalent diagnosis in our series followed by photosensitivity in atopic dermatitis.
Le texte complet de cet article est disponible en PDF.Key words : children, photodermatosis, photosensitivity, phototest, ultraviolet A, ultraviolet B, visible light
Abbreviations used : AD, AP, EPP, MED, PhAD, PLE, UV, VL
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 63 - N° 6
P. 1019-1025 - décembre 2010 Retour au numéro
Article précédent
- Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trial
- Kristian Reich, James Signorovitch, Karthik Ramakrishnan, Andrew P. Yu, Eric Q. Wu, Shiraz R. Gupta, Yanjun Bao, Parvez M. Mulani
- IgM in lesional skin of adults with Henoch-Schönlein purpura is an indication of renal involvement
- Sora Takeuchi, Yoshinao Soma, Tamihiro Kawakami
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?